Bentzen S M, Poulsen H S, Kaae S, Jensen O M, Johansen H, Mouridsen H T, Daugaard S, Arnoldi C
Department of Oncology, Radiumstationen, Aarhus, Denmark.
Cancer. 1988 Jul 1;62(1):194-202. doi: 10.1002/1097-0142(19880701)62:1<194::aid-cncr2820620129>3.0.co;2-8.
A multivariate regression analysis of survival data, using the Cox proportional hazards model (PHM), was performed on the retrospective material of 184 osteosarcoma patients treated at the Aarhus and Copenhagen oncology centers, Denmark, from 1963 to 1984. All patients were previously untreated. Radical surgery, in general ablative when possible, was the primary treatment goal throughout this period. A number of clinical and pathologic variables were tested in the model to elucidate their prognostic importance. Tumors localized to the trunk, pelvis, or femur, and symptom duration of less than 6 months were poor prognostic signs. Tumors dominated by fibroblastic cells and a patient age of approximately 25 to 30 years were associated with an especially good prognosis. The prognosis worsened with advancing age. Children, adolescents, and adults ages 5 to 25 years had significantly poorer prognosis than young adults 25 to 30 years of age. Sex, radiologic appearance, and year of referral had no significant prognostic value in this series. Based on the regression model, a prognostic index is derived and survival is calculated for a good and a poor prognostic case. The overall 10-year survival with one standard deviation was 28.6 +/- 3.5%. Cancer deaths continue to occur 10 years after initial treatment, and the estimated hazard rate is still four times greater than that of a sex- and age-matched group of healthy individuals.
利用Cox比例风险模型(PHM)对生存数据进行多变量回归分析,该分析基于1963年至1984年在丹麦奥胡斯和哥本哈根肿瘤中心接受治疗的184例骨肉瘤患者的回顾性资料。所有患者此前均未接受过治疗。在此期间,根治性手术(尽可能进行广泛切除)是主要治疗目标。在模型中测试了一些临床和病理变量,以阐明它们的预后重要性。肿瘤位于躯干、骨盆或股骨,以及症状持续时间少于6个月是预后不良的迹象。以成纤维细胞为主的肿瘤和年龄约为25至30岁的患者预后特别好。预后随着年龄增长而恶化。5至25岁的儿童、青少年和成年人的预后明显比25至30岁的年轻人差。在该系列中,性别、放射学表现和转诊年份没有显著的预后价值。基于回归模型,得出一个预后指数,并计算出预后良好和预后不良病例的生存率。总体10年生存率及一个标准差为28.6 +/- 3.5%。初始治疗10年后仍有癌症死亡发生,估计风险率仍比性别和年龄匹配的健康个体组高四倍。